Cardiology
Stories
-
Thryv raises $30 million Series B led by InClin to fund Phase 2a ASPIRE-HF heart failure study
Thryv Therapeutics said a $30 million Series B led by the contract research organization InClin will fund the Phase 2a ASPIRE-HF study of THRV-1268. The company said InClin has set up clinical operations in Australia, where enrollment opens in early 2027.
-
Semaglutide 2.4 mg scored 7.3 points above placebo on KCCQ-CSS in HFpEF with type 2 diabetes
In a 617-participant trial, the KCCQ-CSS difference between semaglutide 2.4 mg and placebo was 7.3 points at week 52, the Novo Nordisk record shows. The record now holds results for a completed trial in obesity-related heart failure with preserved ejection fraction and type 2 diabetes.
-
FDA approves first pediatric heart valve built to be expanded as a child grows
Edwards Lifesciences' Autus Size-Adjustable Valve is also the first valve approved in the U.S. with polymeric leaflets instead of animal tissue.